Hengrui Pharma (600276.SH) has released an announcement that several of its products have been included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (referred to as the "National Medical Insurance Catalog").
Through medical insurance negotiations, Zemituostar Tablets, Luzinorel Sodium Tablets, and Henggliflozin-Reglitin-Metformin Hydrochloride Sustained-release Tablets (II) were included in the National Medical Insurance Catalog for the first time; the newly added indication for Reconatumumab Injection for infusion was successfully included in the National Medical Insurance Catalog; Hydroxyethanesulfonic Acid Dalpiciclib Tablets successfully renewed its contract and added a new indication to be included in the National Medical Insurance Catalog; Proline Henggliflozin Tablets, Reviramide Tablets, Tegilidine Fumarate Injection, Otesaconazole Capsules, Henggliflozin-Metformin Sustained-release Tablets (I)/(II), Camrelizumab for Injection, and Pregabalin Sustained-release Tablets successfully renewed their contracts and remain in the National Medical Insurance Catalog.
It is reported that the total sales of the above-mentioned drugs of the company in 2025 are approximately 6.951 billion yuan, and the total sales in the first three quarters of 2026 are approximately 6.860 billion yuan. The inclusion of the above-mentioned drugs in the National Medical Insurance Catalog will be conducive to the sales of the drugs, and the impact on the company's operating performance cannot be estimated for the time being. The National Medical Insurance Catalog (2026) will be officially implemented from January 1, 2027.
Comments